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objective was to test the non-inferiority of overall survival
after IV BU compared to TBI. From March 2009 to February
2011,1,483eligiblepatientswereenrolled (IVBU,n¼1025, TBI,
n¼458) from 120 transplant centers. The 2 cohorts were
similar with respect to median age (45 years), gender (50%
female), race (88% Caucasian), performance status (68%90),
and HCT-CI. Most patients had acute myeloid leukemia (68%
BU, 78% TBI). Disease status was early (51%), intermediate
(18%) and advanced (31%) andwere balanced in both cohorts.
Grafts were primarily PB (77%) frommatched sibling (40%) or
well-matched unrelated donors (48%), balanced in both
cohorts. IVBUregimenswereCY (59%) or Flu (41%) based. 2-yr
probabilities of overall survival (95% CI), were 56% (53-60%)
and 48% (43-54%) for IV BU and TBI, respectively (p¼0.02).
Corresponding probabilities of progression-free survival
(PFS) were 49% (45-52%) and 44% (40-49%), (p¼0.17). The
incidence of hepatic veno-occlusive disease (VOD)/sinusoidal
obstruction syndrome (SOS)was5% forBUand1% for TBI; (p<
0.001). Outcomes were the same for BUþCY and BUþFlu
regimens. There were no differences in engraftment of
neutrophils or platelets, disease relapse, grade 2-4 acute or
chronic GVHD. Multivariate Analysis (MVA) (adjusting for
HCT-CI, disease andstatus, donor type, age, PS, and race) of the
main outcomes is summarized in Table. Compared to TBI, IV
BU was associated with superior survival and no increased
risk of relapse or TRM. These results support the use of mye-
loablative BU- over TBI-based conditioning regimens for
treatment of AML, MDS, and CML.
Table
Cox Proportional Hazards MVA for IV BU vs. TBI
Outcome N IV BU vs. TBI
HR (95% CI)
P-value
OM 1439 0.82 (0.68-0.98) 0.026
TRM 1434 0.81 (0.61-1.08) 0.15
Rel 1434 0.93 (0.76-1.12) 0.43
TF 1434 0.90 (0.77-1.06) 0.19
HR indicats hazard ratio; N, number of subjects; OM, overall mortality; Rel,
relapse; TF, treatment failure, relapse or death; TRM, treatment-related5
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We have previously demonstrated that small numbers of
ex vivo-expanded, trivirus-speciﬁc Tcells targeting EBV, CMV,
and Adv are safe, effective and protective in vivo. However,
broader implementation is limited by the need for infectious
virus/vector, and prolonged (8-12wks) and complex manu-
facture, while antigenic competition limits extension to
additional viruses. We now evaluate whether T-cell lines
manufactured using methods that exclude viral components
and utilize simpliﬁed manufacturing technology can be clin-
ically effective. With NHLBI-PACT support, 29 clinical-grade
rCTL lines have beengenerated. Froman initial 15x106 PBMCs,
mortality.we prepared a median of 21488x106 T-cells (range 100-
420x106) over 9-11 days using DCs nucleofected with DNA
plasmids encoding immunogenic EBV (LMP2, EBNA1 and
BZLF1), Adv (Hexon and Penton), and CMV (pp65 and IE1)
antigens, and expansion with IL4þ7 in G-Rex devices. The
rCTL lines were polyclonal, comprising both CD4þ (333%)
and CD8þ (60.53%) cells, that expressed activation and
memory markers. Twenty lines generated from donors that
wereseropositive for all virusesdemonstratedactivityagainst
all 3 targets - CMV (IE1: 359100; pp65: 637177SFC/2x105),
EBV (LMP2: 21760, EBNA1: 6719 and BZLF1: 11131) and
Adv (Hexon: 26574, Penton: 19153) - while 9 lines
generated from CMV seronegative donors demonstrated
activity exclusively against EBV (LMP2: 19770, EBNA1:
14551 and BZLF1: 23984) and Adv (Hexon: 27196, Pen-
ton: 25490). None of the T-cell lines reacted against
unmodiﬁed recipient cells. To date we have administered
these lines to 10 allogeneic HSCT recipients at doses ranging
from 0.5-2x107/m2 as treatment for CMV (n¼3), Adv (n¼2),
EBV (n¼2), EBVþAdv (n¼1), and CMVþAdv (n¼2). One
patient developed a skin rash 2weeks post-rCTLs but no other
toxicity have been observed. Eight treated patients, including
one with a biopsy-proven EBV lymphoma and the 3 patients
with double reactivations, had complete clinical responses to
rCTL, which corresponded with an increase in the frequency
of virus-speciﬁc T-cells detected in peripheral blood. For CMV
we saw an increase from a median of 0.5 to 96 and 1 to 277
SFC/4x105 IE1 and pp65-speciﬁc T cells, respectively 3-6wks
post-infusion; for Adv an increase from mean 0.5 to 137 and
0.5 to 99 SFC/4x105 Hexon and Penton-speciﬁc cells, respec-
tively, and for EBV an increase from 2.8 to 227,1.5 to 39, and 1
to 188.5 SFC/4x105 EBNA1, LMP2, and BZLF1-speciﬁc T-cells,
respectively. Twopatients failed to respond to rCTLs; onewith
a 3 year history of persistent CMV colitis and one with
elevated EBV DNA; both had high pre-existing virus-speciﬁc
T-cell precursors. rCTLs have been safe and effective in 80% of
treated patients and have the potential to increase the avail-
ability of cell products for HSCT recipients. We are currently
extending this platform to additional viruses.
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Idiopathic pneumonia syndrome (IPS) is a noninfectious
pulmonary disorder occurring acutely post-SCT, associated
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previously established that TNFa is involved the patho-
genesis of the disorder, with elevated levels of TNFa in
both plasma and broncho-alveolar lavage (BAL) ﬂuid of
affected patients. We now report results from a multi-
center, phase II, single arm, open label trial investigating
a soluble TNF binding protein, etanercept (Enbrel, Amgen)
for the treatment of children with IPS. Eligible patients
were <18 years, within 120 days post-SCT, with radio-
graphic evidence of diffuse pulmonary inﬁltrates, and no
evidence of active infection, sepsis syndrome, congestive
heart failure, or iatrogenic ﬂuid overload. Absence of
infection was established by a negative BAL at study entry.
In addition to standard therapy with corticosteroids (2.0
mg/kg/day), patients received etanercept (0.4 mg/kg/dose)
twice weekly x 8 doses. Steroid taper was allowed after 7
days, per investigator discretion. Response was deﬁned as
survival to day 28 plus complete discontinuation of all
supplemental oxygen support for >72 hours within the 28
day period. We enrolled 39 patients (median age 11y,
range 1-17y) between 2006 - 2011. Eleven patients were
ineligible for study treatment due to evidence of infection
by BAL, with the remaining 28 patients receiving study
therapy. At study entry, the median baseline FiO2 was 45%,
and 17 patients were mechanically ventilated. Complete
responses were seen in 20 (71%) of 28 patients, with
a median time to response 10 days (range 1-24). There
were no signiﬁcant differences in response based upon
age, gender, stem cell source, donor type, conditioning (TBI
vs non-TBI), or HLA match. Response rates were signiﬁ-
cantly higher for patients not requiring mechanical venti-
lation at study entry (100% vs 53%, p¼0.01). A non-
signiﬁcant trend towards improved response was seen in
patients treated within the initial 3 days of requiring
supplemental oxygen (83% vs 50%, p¼0.09). When
compared to historical reports, the combination of eta-
nercept plus corticosteroids was associated with strikingly
high overall survival at day 28 [89% (95% CI: 70-96)] and at
1-year [63% (95% CI: 42-79)]. Serious infectious complica-
tions during study therapy included HSV (2), CMV (2),
fungal (1), and enterocolitis (1). Grade 3-5 organ toxicities
included renal (2), GI bleed (1), hepatic (1), and CNS (2). In
conclusion, the addition of etanercept to high dose corti-
costeroids was associated with high response rates and
survival in children with IPS. Response rates were highest
in patients who did not require mechanical ventilation at
initiation of therapy. Therapy was well tolerated in this
high risk patient population. Given these promising results,
further study in children comparing this approach to
standard therapy is warranted.ORAL PRESENTATIONS
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Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds
the Flt3 (CD135) receptor expressed on hematopoietic stem
cells (HSC), early progenitor cells, immature thymocytes, and
steady state dendritic cells and induces the proliferation,
differentiation, development and mobilization of these cells
in the bone marrow, peripheral blood, and lymphoid organs.
Given its potential as a stem cell mobilizer and immuno-
therapeutic, the safety and biologic activity of recombinant
human (rh) Flt3L were originally demonstrated in clinical
studies conducted by Immunex Inc. Development has
recently been reinitiatedwith CDX-301,which is composed of
the identical amino acid sequence and comparable biologic
activity as the product ﬁrst tested by Immunex. A Phase 1 trial
was initiated to assess the safety, pharmacokinetic, pharma-
codynamic and immunologic proﬁle of CDX-301. Using
a standard 3þ3 dose-escalating design, subjects receive daily
subcutaneous injectionof CDX-301at adose level of 1, 3,10, 25
or 75 mcg/kg x 5 days (Cohorts 1-5), 25 mcg/kg x 7 days
(Cohort 6), or 25mcg/kg x 10 days (Cohort 7), followed by 28-
day observation. 30 healthy volunteers (HV) (67% male,
median age¼ 34 years) have been enrolled. All HV in Cohorts
1-6 have completed dosing; CDX-301 administration
continues for Cohort 7. In Cohort 5, one HV with a remote
history of community acquired pneumonia was hospitalized
with community acquired pneumonia which developed on
study day 12; the event responded rapidly to antibiotic
treatment and fully recovered within 2 weeks, but was
considered a dose-limiting toxicity given the temporal asso-
ciation with CDX-301 administration. The cohort was
